Abstract:Objective To investigate the efficacy and safety of recombinant human interleukin (rhIL)-11 combined with glucocorticoid in treatment of newly diagnosed immune thrombocytopenia (ITP) patients.Methods From December 2011 to December 2013,a total of 60 cases of newly diagnosed ITP patients who were received in First People's Hospital of Zhangjiagang were collected into this study.These 60 cases of ITP patients were randomly divided into two groups,as study group (n=30) and control group (n=30) by simple random samping method.The study group was used rhIL-11 combined with glucocorticoid,and control group was used glucocorticoid only.The study inclusion criteria were newly diagnosed ITP patients who were older than 18 years old.Secondary thrombocytopenia and ITP accompanied with other diseases,for example diabete,cardiac insufficiency and arrhythmia were excluded.Two groups' platelet count prior treatment,after 4 days and 7 days treatments,and average time of platelet count which is greater than or equal to 100 × 109/L were tested.Bleeding score,therapeutic efficiency evaluation and adverse reactions after 7 days treatment were calculated.The study protocol was approved by the Ethical Review Board of Investigation in Human at First People's Hospital of Zhangjiagang.Informed consent was obtained from all participants.There were no significant differences of patients' clinical data in two groups,such as age and gender composition,platelet count and bleeding score before treatment (P＞ 0.05).Results ①Platelet counts of both groups were increased gradually after treatment,but platelet count in study group [(37.9±30.4) × 109/L] was higher than that of the control group [(22.5±16.0) × 109/L] after 4 days treatment.The difference was statistically significant(t=2.308,P=0.028).Platelet count in study group[(121.8±29.2)× 109/L] was also higher than that of control group[(91.2±28.7)× 109/L] after 7 days treatment,the difference was statistically significant(t=5.444,P=0.000).In study group,the time [(7.0 ±1.4) d] that platelet count recovered greater than or equal to 100 × 109/L was shorter than that of control group [(9.3 ± 3.5) d],the difference was statistically significant (t =-3.820,P =0.001).(②) Bleeding score evaluated by ITP-bleeding assessment tool (BAT) was decreased gradually in two groups after treatment.But bleeding score of study group[(2.0±± 1.1) score] was significantly lower than that of the control group [(2.7± 1.0) score] after 4 days treatment,the difference was statistically significant(t=-2.588,P=0.015).The bleeding score of study group[(0.1 ± 0.4) score] was also significantly lower than that of the control group[(0.5 ± 1.2) score] after 7 days treatment,the difference was statistically significant(t=-2.249,P=0.032).③ The total effective rate was 90.0％ in study group,but 60.0％ in control group after 7 days treatment,and the difference was statistically significant (x2 =5.69,P＜0.05).④ In study group,6 cases(20.0％,6/30) had water-sodium retention and relieved by diuretics.Three cases (10.0 ％,3/30)had arrhythmia.2 cases(6.7 ％,2/30) had atrial premature beats noted on electrocardiogram (ECG).One case (3.3 ％,1/30) had atrial fibrillation,and recovered after injection lantoside C (cedilanid)and stopping rhIL-11 subscutaneous injection.20 cases(66.7 ％,20/30) had bulbar conjunctiva hyperemia,but needn't treatment.Among these patients,two cases in study group had two adverse affects.In control group,5 cases(16.7 ％,5/30) had slight weight gain without edema lower extremity,but needn't treatment.And 2 cases (6.7％,2/30) had sinus tachycardia,and recovered after stopping rhIL-11 subscutaneous injection.Others had no adverse affects.Conclusions rhIL-11 combined with glucocorticoid therapeutic regimen for newly diagnosed ITP took action faster and had significant effect.At the same time,adverse affects were tolerable.

Effectiveness of shengxuexiaoban capsules combined with glucocorticoid therapy for immune thrombocytopenia: A meta-analysis

[Efficacy and Safety of Low-Dose Rituximab Combined with Different Dosage of Glucocorticoids for Immune Thrombocytopenia].

Romiplostim in Primary Immune Thrombocytopenia That is Persistent or Chronic: Phase III Multicenter, Randomized, Placebo-Controlled Clinical Trial in China

Efficacy and Safety of Eltrombopag in Chinese Patients with Chronic Immune Thrombocytopenia: Stage 2 Results from a Multicenter Phase III Study.

Efficacy and Safety of Glucocorticoids in Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study

Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis

Efficacy of caffeic acid tablets combined with glucocorticoid in treatment of primary immune thrombocytopenia

[A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid].

Efficacy and Safety Analysis of Combination Therapy Consisting of Intravenous Immunoglobulin and Corticosteroids versus Respective Monotherapies in the Treatment of Relapsed ITP in Adults

Analysis of Clinical Effects and Mechanism of Recombinant Human Interleukin-11 with Glucocorticoids for Treatment of Idiopathic Thrombocytopenic Purpura.

Classificatory Treatment of Refractory Idiopathic Thrombocytopenic Purpura

[Curative Efficacy of Rituximab for ITP Patients with Different Sensitivity to Hormone].

Analysis of therapeutic effect of recombinant human interleukin-11 combined with glucocorticoid in treatment of immune thrombocytopenia

Efficacy and Safety of Glucocorticoids Therapy for IgA Nephropathy: a Meta-Analysis of Randomized Controlled Trials.

Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia

Immunological Characteristics and Effect of Cyclosporin in Patients with Immune Thrombocytopenia

Clinical Analysis on Children Acute Thrombocytopenia-absent Radii Syndrome (ITP)

Combination therapy of dexamethasone, rituximab, and cyclosporine for adults with primary immune thrombocytopenia: a prospective observational study

Observation on the high dose dexamethasone combined with recombinant human interleukin-11 in the treatment of the patients with newly diagnosed primary immune thrombocytopenia

Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia